*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>Aptinib (also known as Olmutinib) is a third-generation EGFR tyrosine kinase inhibitor developed for treating non-small cell lung cancer. Its core synthesis involves complex heterocyclic coupling reactions. <strong>Molecular Formula</strong>: C<sub>21</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>; <strong>CAS Number</strong>: 1496876-23-7.</p>
<h3>Application</h3>
<ul>
<li>Pharmaceutical manufacturing for oncology drug formulations targeting T790M mutations.</li>
<li>Research and development of novel kinase inhibitors in academic institutions.</li>
<li>Distribution to clinical trial centers for Phase III efficacy studies.</li>
</ul>
<h3>Precautions</h3>
<p>Strictly regulated for human use only; requires storage below 25°C in a dry, dark environment. Handling must comply with GMP standards to prevent exposure to dust or vapors due to potential cytotoxicity.</p>